摘要
目的:探讨N0期患者癌症复发、转移后的相关生存预后因素。方法:回顾性分析我院2005年8月～2007年8月新诊断复发、转移符合条件的67例N0期食管鳞癌术后患者,根据患者的临床病理特征、治疗方式,分析与生存相关的临床因素。结果:复发后1年生存率为31.34%,2年生存率为10.45%,3年生存率为7.50%。局部复发手术切除后患者预后较好,而淋巴结转移患者居次,脏器转移预后最差。淋巴结转移患者运用同步化放疗效果较好,脏器转移患者化疗效果一般。复发类型是影响患者的独立预后因素。结论:N0期食管鳞癌术后复发生存较差,特别是在独立预后因子远处器官转移的患者。同步化放疗可能有利于提高淋巴结转移患者的术后复发生存时间,而对于脏器转移的患者支持治疗是可选的。
Objective： To explore the prognosis of patients with postoperative recurrent esophageal squamous cell carcinoma in stage N0.Methods： Clinical data of 69 patients with postoperative recurrent esophageal squamous cell carcinoma in stage N0 admitted in 2005 and 2006 were analyzed retrospectively.The clinical factors relative to survive were analyzed based on clinical pathological character,treatment,etc.Results： The 1-year,2-year and 3-year survival rate after recurrence was 31.34%,10.45%,7.5%,respectively.The prognosis was best in patients with local section,followed by lymph node metastasis patients and organ metastasis patients.The effect of chemotherapy was fair.Recurrence type was common.influencing factor on prognosis.Conclusion： The prognosis of postoperative recurrent esophageal squamous cell carcinoma in stage N0 is poor,especially in patients with distant organ metastasis.The chemoradiotherapy may improve the survival time of patients with lymph node metastasis,and is an option for treatment of distant organ metastasis.
出处
《海南医学院学报》
CAS
2011年第12期1711-1712,1715,共3页
Journal of Hainan Medical University
基金
海南医学院科研基金资助学报项目(0020110474)~~
关键词
食管癌
N0期
复发
化放疗
预后
Esophageal squmous cell carcinorma
N0 stage
Chemoradiotherapy
Prognosis
